Erika Alfambra

Zaragoza, AR 50009, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Plasma protein glycosylation: a biomarker for predicting metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.

Plasma protein glycosylation: a biomarker for predicting metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.

Journal: Revista espanola de enfermedades digestivas

Published: November 17, 2025

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Journal: Revista espanola de enfermedades digestivas

Published: September 29, 2025

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Journal: Revista espanola de enfermedades digestivas

Published: September 29, 2025

Healthy Lifestyle Is a Protective Factor from Moderate and Severe Relapses and Steroid Use in Inflammatory Bowel Disease: A Prospective Cohort Study.

Healthy Lifestyle Is a Protective Factor from Moderate and Severe Relapses and Steroid Use in Inflammatory Bowel Disease: A Prospective Cohort Study.

Journal: Inflammatory bowel diseases

Published: January 13, 2024

When metabolic comorbidities and risk of malnutrition coexist: The new era of inflammatory bowel disease.

When metabolic comorbidities and risk of malnutrition coexist: The new era of inflammatory bowel disease.

Journal: The American journal of the medical sciences

Published: December 04, 2023

Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).

Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).

Journal: Gastroenterologia y hepatologia

Published: November 09, 2023

Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry.

Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry.

Journal: Digestive diseases (Basel, Switzerland)

Published: September 13, 2023

A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study).

A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study).

Journal: Gastroenterologia y hepatologia

Published: September 07, 2023

Cardiovascular risk assessment in inflammatory bowel disease with metabolic dysfunction-associated steatotic liver disease.

Cardiovascular risk assessment in inflammatory bowel disease with metabolic dysfunction-associated steatotic liver disease.

Journal: Medicina clinica

Published: September 05, 2023

Lifestyle Can Exert a Significant Impact on the Development of Metabolic Complications and Quality Life in Patients with Inflammatory Bowel Disease.

Lifestyle Can Exert a Significant Impact on the Development of Metabolic Complications and Quality Life in Patients with Inflammatory Bowel Disease.

Journal: Nutrients

Published: August 24, 2023

Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.

Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease.

Journal: European journal of internal medicine

Published: August 02, 2023

Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP.

Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP.

Journal: Journal of clinical medicine

Published: May 15, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026